Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 16,671 Shares of Stock

Key Points

• Major shareholder Endurance (Cayman) Ltd Svf sold 16,671 shares of Vir Biotechnology stock at an average price of $6.07, totaling approximately $101,192.97. This sale represents a 0.11% decrease in their ownership.
• Vir Biotechnology's stock price recently decreased by 0.3%, closing at $5.78, with a market cap of $802.96 million and a reported earnings per share of (-$0.80).
• Several institutional investors have increased their holdings in Vir Biotechnology, with Apollon Wealth Management LLC growing its stake by 100% during the third quarter.

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 16,671 shares of the stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $6.07, for a total value of $101,192.97. Following the completion of the sale, the insider directly owned 15,353,338 shares of the company's stock, valued at approximately $93,194,761.66. This represents a 0.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.10, for a total value of $78,348.40.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.08, for a total value of $13,984.00.
• On Thursday, October 9th, Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.14, for a total value of $1,529,228.40.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.05, for a total value of $2,820,764.10.
• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.60, for a total value of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.69, for a total value of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.56, for a total value of $2,503,901.52.

Vir Biotechnology Stock Down 0.3%

Shares of VIR traded down $0.02 during midday trading on Friday, reaching $5.78. 1,071,614 shares of the stock were exchanged, compared to its average volume of 1,537,480. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $14.45. The firm has a 50 day simple moving average of $5.13 and a 200-day simple moving average of $5.28. The company has a market cap of $802.96 million, a price-to-earnings ratio of -1.45 and a beta of 1.27.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.08). The firm had revenue of $1.21 million for the quarter, compared to analysts' expectations of $2.38 million. Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The firm's revenue for the quarter was down 60.5% on a year-over-year basis. During the same period last year, the business earned ($1.02) earnings per share. Research analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Institutional Trading of Vir Biotechnology

Several institutional investors have recently modified their holdings of the company. Apollon Wealth Management LLC grew its holdings in shares of Vir Biotechnology by 100.0% during the 3rd quarter. Apollon Wealth Management LLC now owns 20,000 shares of the company's stock worth $114,000 after purchasing an additional 10,000 shares in the last quarter. Clarius Group LLC grew its holdings in shares of Vir Biotechnology by 0.3% during the 3rd quarter. Clarius Group LLC now owns 619,312 shares of the company's stock worth $3,536,000 after purchasing an additional 1,777 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Vir Biotechnology by 99.9% during the 2nd quarter. Squarepoint Ops LLC now owns 107,360 shares of the company's stock worth $541,000 after purchasing an additional 53,662 shares in the last quarter. Hudson Bay Capital Management LP grew its holdings in shares of Vir Biotechnology by 17.7% during the 2nd quarter. Hudson Bay Capital Management LP now owns 696,000 shares of the company's stock worth $3,508,000 after purchasing an additional 104,580 shares in the last quarter. Finally, Public Sector Pension Investment Board grew its holdings in shares of Vir Biotechnology by 7.4% during the 2nd quarter. Public Sector Pension Investment Board now owns 314,176 shares of the company's stock worth $1,583,000 after purchasing an additional 21,598 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on VIR shares. Bank of America raised Vir Biotechnology from a "neutral" rating to a "buy" rating and increased their price objective for the company from $12.00 to $14.00 in a report on Wednesday, August 27th. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Vir Biotechnology in a report on Monday, September 15th. Raymond James Financial started coverage on Vir Biotechnology in a report on Friday, July 11th. They issued an "outperform" rating on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vir Biotechnology in a research report on Tuesday. Finally, Evercore ISI started coverage on shares of Vir Biotechnology in a research note on Wednesday, September 3rd. They issued an "outperform" rating and a $12.00 price objective on the stock. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $17.30.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.